STOCK TITAN

CohBar Inc - CWBR STOCK NEWS

Welcome to our dedicated news page for CohBar (Ticker: CWBR), a resource for investors and traders seeking the latest updates and insights on CohBar.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CohBar's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CohBar's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences
CohBar Inc

Nasdaq:CWBR

CWBR Rankings

CWBR Stock Data

2.33M
2.48M
15.09%
6.26%
0.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Menlo Park

About CWBR

cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.